The major significant difference between proIL-33 and mtrIL-33 was that proIL-33 was able to increase E7-antigen specific IgG levels. However, because mtrIL-33 induced 90% tumor regression, it suggested that T cells mediated the anti-tumor protection, not B-cell responses.
the data suggests that
proIL-33 could also be useful in vaccine strategies aiming to achieve enhanced antibody
responses and cellular immunity. This is an area offurther investigation.